Ibogaine Therapy

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Opioid addiction (heroin, fentanyl, prescription opioids)Cocaine and stimulant addictionAlcohol dependenceExploratory: PTSD, depression, anxiety

Mechanism

Ibogaine acts as a 'psychoplastogen' influencing multiple neurotransmitter systems. It antagonizes NMDA receptors, modulates kappa- and mu-opioid receptors, interacts with sigma-2 receptors, and increases levels of GDNF (glial cell line-derived neurotrophic factor), potentially resetting dysregulated reward pathways. Its long-lived metabolite, noribogaine, prolongs effects by modulating serotonin transporters and opioid receptors.

Protocol

Preparation

Comprehensive medical screening including ECG, electrolytes, liver function. Pre-treatment abstinence from QT-prolonging substances.

Procedure

Oral administration of ibogaine under medical supervision
Continuous cardiac monitoring and emergency readiness
Psychedelic experience lasting 12–24 hours with visions and deep introspection
Integration therapy following acute effects

Frequency: Single-dose intervention; occasional boosters may be used

Duration: Psychedelic phase 12–24 hours; integration over weeks to months

Total Treatment Time: Acute intervention with extended follow-up

Expected Outcomes

Immediate

Reduction in opioid withdrawal symptoms
Profound visionary experience

Short Term

Reduced cravings, enhanced motivation to abstain
Introspective psychological breakthroughs

Long Term

Possible sustained remission from substance use; outcomes vary significantly

Side Effects

common

Nausea
Vomiting
Ataxia
Insomnia during acute phase

uncommon

Severe anxiety
Transient paranoia

rare

Fatal arrhythmias
Seizures
Sudden cardiac death

Contraindications

absolute

Cardiac disease
Pregnancy
Severe liver dysfunction

relative

Concurrent psychiatric instability
Lack of medical monitoring availability

special considerations

Should only be administered in medical settings with emergency response capacity

Research Evidence

Key Studies

Observational studies report reduced opioid withdrawal and craving after single ibogaine sessions
Small open-label trials suggest potential benefit for stimulant addiction
Preclinical research supports neurotrophic and anti-addictive properties

Limitations

No large-scale randomized controlled trials; high safety risks; legal barriers

Cost Considerations

typical session cost: $5,000–$10,000 (in international clinics)

total treatment cost: Variable; often out-of-pocket as not covered by insurance

insurance coverage: Not covered in most jurisdictions due to Schedule I status

cost effectiveness: Unclear due to limited evidence and high safety risk

ux display: undefined

collapsible: undefined

heading: undefined

Integration Support

Concurrent Therapies

Psychotherapy (especially trauma-informed)
Medication-assisted treatment (if needed after relapse)
Support groups for addiction recovery

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists